Insights into the pathophysiology and treatment of patients with calcium oxalate nephrolithiasis.
Assimos
D G
DG
D002021:Buffers; D002118:Calcium / Q000652:urine; D002128:Calcium Metabolism Disorders / Q000652:urine; D002129:Calcium Oxalate / Q000652:urine*; D006801:Humans; D007669:Kidney Calculi / Q000737:chemistry / Q000503:physiopathology / Q000628:therapy / Q000652:urine*; D008970:Molecular Weight; D010710:Phosphates / Q000627:therapeutic use; D017680:Potassium Compounds / Q000627:therapeutic use; D015842:Serine Proteinase Inhibitors / Q000652:urine*; D012737:Sex Factors; D000515:alpha 1-Antitrypsin / Q000652:urine*
D002021:Buffers; D010710:Phosphates; D017680:Potassium Compounds; D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin; D002129:Calcium Oxalate; C013216:potassium phosphate; D002118:Calcium